The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis ; volume:24 ; number:1 ; day:12 ; month:11 ; year:2024 ; pages:1-9 ; date:12.2024
BMC gastroenterology ; 24, Heft 1 (12.11.2024), 1-9, 12.2024
- Urheber
-
Hu, Xinyue
Tang, Xiaowei
Li, Limin
Luo, Lian
He, Xinsen
Yan, Qin
Zhong, Xiaolin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12876-024-03480-9
- URN
-
urn:nbn:de:101:1-2501292107316.170178181811
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hu, Xinyue
- Tang, Xiaowei
- Li, Limin
- Luo, Lian
- He, Xinsen
- Yan, Qin
- Zhong, Xiaolin
- SpringerLink (Online service)
Ähnliche Objekte (12)
PF-06438179/GP1111: An Infliximab Biosimilar
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
PF-06438179/GP1111: An Infliximab Biosimilar
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
PF-06438179/GP1111: An Infliximab Biosimilar
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching